Manipulation of the cytoplasmic and transmembrane domains alters cell surface levels of the coxsackie-adenovirus receptor and changes the efficiency of adenovirus infection

被引:22
作者
Van't Hof, W
Crystal, RG
机构
[1] Cornell Univ, Weill Med Coll, Inst Med Genet, New York, NY 10021 USA
[2] Cornell Univ, Weill Med Coll, Div Pulm & Crit Care Med, New York, NY 10021 USA
关键词
D O I
10.1089/104303401450933
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Expression of the coxsackie-adenovirus receptor (CAR) is a critical determinant En cellular susceptibility to infection with adenovirus-based gene transfer vectors. This study is focused on the hypothesis that manipulation of the cytoplasmic tail and transmembrane regions of CAR can be used to change cell surface levels of CAR and, consequently, to alter the efficiency of Ad-mediated gene transfer. To accomplish this, Flag-tagged ([F]) human CAR ([F]CAR), [F]tailless-CAR (lacking the cytoplasmic tail), and [F]GPI-CAR (containing a GPI lipid anchor instead of the transmembrane and cytoplasmic regions) were exogenously expressed in CHO cells. Analysis of I-125-labeled anti-Flag antibody binding to transfected cells revealed that [F]tailless-CAR and [F]GPI-CAR were expressed on the cell surface in 1.8- to 2.5-fold higher amounts than [F]CAR, while the total expression levels were similar. Infection with replication-deficient adenovirus encoding beta -galactosidase (Ad-beta gal) demonstrated 1.5- to 2-fold higher levels of transgene expression in CHO cells expressing [F]tailless-CAR or [F]GPI-CAR, respectively, compared with cells containing [F]CAR. The form of CAR expressed did not affect the transport of fluorescent Cy3-Ad particles from the cell surface to the nuclear region. These observations indicate that transduction of target cells by Ad vectors can be optimized by increasing cell surface levels of CAR through functional deletion of the tail and membrane protein domains.
引用
收藏
页码:25 / 34
页数:10
相关论文
共 45 条
[1]   VITRONECTIN RECEPTOR ANTIBODIES INHIBIT INFECTION OF HELA AND A549 CELLS BY ADENOVIRUS-TYPE-12 BUT NOT BY ADENOVIRUS TYPE-2 [J].
BAI, M ;
CAMPISI, L ;
FREIMUTH, P .
JOURNAL OF VIROLOGY, 1994, 68 (09) :5925-5932
[2]   INTERNALIZATION OF GLYCOSYL-PHOSPHATIDYLINOSITOL (GPI)-ANCHORED LYMPHOCYTE PROTEINS .2. GPI-ANCHORED AND TRANSMEMBRANE MOLECULES INTERNALIZE THROUGH DISTINCT PATHWAYS [J].
BAMEZAI, A ;
GOLDMACHER, VS ;
ROCK, KL .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1992, 22 (01) :15-21
[3]   Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5 [J].
Bergelson, JM ;
Cunningham, JA ;
Droguett, G ;
KurtJones, EA ;
Krithivas, A ;
Hong, JS ;
Horwitz, MS ;
Crowell, RL ;
Finberg, RW .
SCIENCE, 1997, 275 (5304) :1320-1323
[4]   Receptors mediating adenovirus attachment and internalization [J].
Bergelson, JM .
BIOCHEMICAL PHARMACOLOGY, 1999, 57 (09) :975-979
[5]   The murine CAR homolog is a receptor for coxsackie B viruses and adenoviruses [J].
Bergelson, JM ;
Krithivas, A ;
Celi, L ;
Droguett, G ;
Horwitz, MS ;
Wickham, T ;
Crowell, RL ;
Finberg, RW .
JOURNAL OF VIROLOGY, 1998, 72 (01) :415-419
[6]   Structural analysis of the mechanism of adenovirus binding to its human cellular receptor, CAR [J].
Bewley, MC ;
Springer, K ;
Zhang, YB ;
Freimuth, P ;
Flanagan, JM .
SCIENCE, 1999, 286 (5444) :1579-1583
[7]   Molecular bases for the recognition of tyrosine-based sorting signals [J].
Bonifacino, JS ;
Dell'Angelica, EC .
JOURNAL OF CELL BIOLOGY, 1999, 145 (05) :923-926
[8]   Status of gene therapy for cystic fibrosis lung disease [J].
Boucher, RC .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 103 (04) :441-445
[9]   The human HLA-A*0201 allele, expressed in hamster cells, is not a high-affinity receptor for adenovirus type 5 fiber [J].
Davison, E ;
Kirby, I ;
Elliott, T ;
Santis, G .
JOURNAL OF VIROLOGY, 1999, 73 (05) :4513-4517
[10]   Integrin alpha 5 beta 1-mediated adenovirus infection is enhanced by the integrin-activating antibody TS2/16 [J].
Davison, E ;
Diaz, RM ;
Hart, IR ;
Santis, G ;
Marshall, JF .
JOURNAL OF VIROLOGY, 1997, 71 (08) :6204-6207